N. Vogelzang

I. Wistuba, K. Kelly, D. Gandara, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

G. Scagliotti, T. Nakano, J. V. van Meerbeeck, 2017, Clinical lung cancer.

Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.

Heber MacMahon, Samuel G Armato, Adam Starkey, 2004, Medical physics.

Variability in mesothelioma tumor response classification.

Heber MacMahon, Samuel G Armato, Adam Starkey, 2006, AJR. American journal of roentgenology.

Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma

J. Holland, M. Ratain, David Palchak, 2004, Cancer.

Future directions for gemcitabine in the treatment of genitourinary cancer.

N. Vogelzang, 2002, Seminars in oncology.

Docetaxel and exisulind in hormone-refractory prostate cancer.

C. Ryan, W. Stadler, N. Vogelzang, 2001, Seminars in oncology.

Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report).

R. Weichselbaum, N. Vogelzang, G. Chodak, 1991, International journal of radiation oncology, biology, physics.

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

David A. Smith, D. V. Von Hoff, L. Marton, 2020, Cancer Chemotherapy and Pharmacology.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

David C. Smith, G. Shapiro, R. Kurzrock, 2017 .

Phase I I T rial o f a S ingle W eekly I ntravenous D ose o f Ranpirnase i n P atients W ith U nresectable M alignant Mesothelioma

S. McCachren, R. Fine, N. Vogelzang, 2002 .

Chemotherapy for malignant pleural mesothelioma

N. Vogelzang, 2008, The Lancet.

Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.

I. Gill, D. Quinn, N. Vogelzang, 2020, Clinical genitourinary cancer.

Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.

N. Vogelzang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.

E. Heath, D. Dang, S. Chun, 2008, Cancer research.

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

G. Sonpavde, M. Galsky, C. Sternberg, 2010, The Lancet. Oncology.

Systemic therapy for metastatic urothelial carcinoma

Chih-Hung Hsu, Y. Pu, Chia‐Chi Lin, 2008, BJU international.

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.

G. Sonpavde, M. Galsky, C. Sternberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.

R. Schilsky, M. Ratain, R. Mick, 1996, Pharmacogenetics.

Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.

E. Small, N. Vogelzang, S. Halabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment

S. Plumb, S. Mohile, N. Vogelzang, 2022, The oncologist.

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

P. Kantoff, E. Small, D. Hayes, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Current clinical trial design issues in hormone‐refractory prostate carcinoma

A. Zietman, E. Crawford, N. Vogelzang, 1998, Cancer.

Sequential Therapy in Metastatic Renal Cell Carcinoma

J. Burke, B. Hirsch, N. Vogelzang, 2016, Journal of kidney cancer and VHL.

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

A. Kibel, C. Drake, E. Antonarakis, 2016, Clinical Cancer Research.

A medical oncologist’s approach to immunotherapy for advanced renal tumors: Is nephrectomy indicated?

N. Vogelzang, M. Cooney, S. Remick, 2004, Current urology reports.

Conditional Survival in de novo Metastatic Urothelial Carcinoma

N. Vogelzang, S. Pal, R. Nelson, 2015, PloS one.

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

E. Small, N. Vogelzang, A. Hussain, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.

J. Nelson, M. Carducci, J. Breul, 2003, The Journal of urology.

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)

I. Thompson, C. Tangen, N. Agarwal, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

I. Thompson, C. Tangen, N. Agarwal, 2020, Prostate Cancer and Prostatic Diseases.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

E. Basch, A. Bennett, H. Scher, 2019, European urology.

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

J. Burke, J. Hainsworth, C. Sternberg, 2017, European urology.

SECONDARY HORMONAL MANIPULATIONS IN THE TREATMENT OF CASTRATION REFRACTORY PROSTATE CANCER

N. Agarwal, N. Vogelzang, 2011, BJU international.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

E. Small, Y. Whang, J. Picus, 2011, Cancer.

A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.

Sunil Sharma, N. Vogelzang, J. Symanowski, 2008, Translational oncology.

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

P. Schellhammer, N. Vogelzang, M. Soloway, 1999, The Prostate.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1995, Urology.

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

T. Powles, N. Vogelzang, J. Bellmunt, 2017, Cancer treatment reviews.

Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US

E. Jonasch, N. Vogelzang, W. Reichmann, 2016, Journal of medical economics.

Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study

P. Kantoff, E. Small, N. Vogelzang, 2007, Clinical Cancer Research.

Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study.

F. Mostofi, D. Stablein, I. Sesterhenn, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

M. Kattan, C. Parker, S. Nilsson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Monitoring response, prediction methodology, staging, and imaging in prostate cancer.

N. Vogelzang, D. Pomerantz, 2006, Reviews in urology.

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

I. Thompson, C. Tangen, N. Agarwal, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.

N. Vogelzang, M. Anderson, M. Chang, 2022, Clinical genitourinary cancer.

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

F. Feng, C. Higano, A. Bryce, 2020, Clinical Cancer Research.

Pharmacokinetics and pharmacodynamics of long‐term continuous‐infusion doxorubicin

M. Ratain, S. Ackland, N. Vogelzang, 1989, Clinical pharmacology and therapeutics.

Phase I and pharmacological study of vinblastine by prolonged continuous infusion.

M. Ratain, N. Vogelzang, 1986, Cancer research.

Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions.

N. Vogelzang, T. Lestingi, G. Sudakoff, 1994, Human gene therapy.

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.

R. Schilsky, M. Ratain, N. Vogelzang, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805

E. Plimack, D. Cella, R. DiPaola, 2022, The Prostate.

A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

J. Marshall, M. Ernstoff, N. Vogelzang, 2011, Journal of immunotherapy.

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA)

C. Parker, N. James, P. Hoskin, 2012 .

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression

P. Schellhammer, N. Vogelzang, Yusong Chen, 1996, Cancer.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Claude Denham, Salih Emri, Nicholas J Vogelzang, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL

P. Atadja, H. Pass, L. Zawel, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors

Sunil Sharma, N. Vogelzang, J. Symanowski, 2009, Investigational New Drugs.

Newer Issues in Mesothelioma Chemotherapy

H. Pass, N. Vogelzang, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma

N. Pavlakis, N. Vogelzang, 2006, Expert opinion on biological therapy.

Commentary (Vogelzang/Manno): Update on Malignant Mesothelioma

N. Vogelzang, Facp., P. Manno, 2005 .

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

K. Nackaerts, J. von Pawel, U. Gatzemeier, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-Line Chemotherapy

N. Pavlakis, N. Vogelzang, 2005 .

Standard therapy for the treatment of malignant pleural mesothelioma.

N. Vogelzang, 2005, Lung cancer.

Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin

N. Vogelzang, B. Kennedy, J. Torkelson, 1985, Cancer.

Coronary artery disease after treatment with bleomycin and vinblastine.

N. Vogelzang, B. Kennedy, D. Frenning, 1980, Cancer treatment reports.

Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer

J. Sosman, C. Higano, E. Small, 2004, Clinical Cancer Research.

Androgen and germ cell testicular cancers.

N. Vogelzang, H. Schoenberg, G. Chodak, 1986, JAMA.

Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.

J. Wolter, N. Vogelzang, P. Bonomi, 1978, Cancer treatment reports.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin

R. Schilsky, M. Ratain, E. Vokes, 1996, Cancer Chemotherapy and Pharmacology.

Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

N. Vogelzang, T. Karrison, 1999, Cancer.

IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

J. Rosenberg, J. Bellmunt, D. Petrylak, 2016 .

Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study.

P. Hegde, T. Powles, H. Burris, 2015 .

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

C. Parker, J. Michalski, S. Nilsson, 2016, European urology.

Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.

E. Jonasch, N. Vogelzang, W. Reichmann, 2015 .

2509 Overall survival analysis from a randomised phase III trial of axitini vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2015 .

Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.

W. Stadler, N. Vogelzang, M. Mahowald, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer

R. Schilsky, M. Ratain, F. Innocenti, 2007, Cancer Chemotherapy and Pharmacology.

A Phase II trial of suramin monthly × 3 for hormone‐refractory prostate carcinoma

Walter M Stadler, Mark J Ratain, Nicholas J Vogelzang, 2004, Cancer.

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

M. Ratain, E. Vokes, C. Ryan, 2002, Cancer Chemotherapy and Pharmacology.

Mineralocorticoid insufficiency due to suramin therapy

M. Ratain, E. Vokes, N. Vogelzang, 1996, Cancer.

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy.

P. Schellhammer, G. Kennealey, N. Vogelzang, 1995, The Journal of urology.

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

A. Bryce, W. Abida, Jingsong Zhang, 2019, Annals of Oncology.

A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies.

G. Shapiro, K. Bhalla, C. Britten, 2016, Journal of Clinical Oncology.

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

D. Smith, E. Small, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy

R. Figlin, K. Flaherty, M. Michaelson, 2012, Cancer.

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion

R. Schilsky, M. Ratain, N. Vogelzang, 2004, Cancer Chemotherapy and Pharmacology.

The cure of bladder cancer: the need for multidisciplinary efforts.

W. Stadler, N. Vogelzang, D. Rukstalis, 1994, The Journal of urology.

Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience.

R. Weichselbaum, N. Vogelzang, G. Chodak, 1993, The Journal of urology.

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

T. Ho, S. Millis, A. Bryce, 2015, Cancer Immunology Research.

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

J. Herndon, N. Vogelzang, M. Green, 2001, Lung cancer.

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

R. DiPaola, M. Carducci, M. Kohli, 2016 .

Ra-223 experience in pretreated patients: EAP setting.

A. Iagaru, M. Morris, A. Dicker, 2015 .

Insurance Status as a Prognostic Factor for Stage and Survival of Testicular Cancer Patients in Illinois

J. Chmiel, S. Sener, N. Vogelzang, 1994 .

Androgen R eceptor M utations i n A ndrogen-Indepen dent Prostate C ancer: C ancer a nd L eukemia G roup B S tudy 9 663

P. Kantoff, E. Small, B. Woda, 2003 .

Development and validation of a scale to measure disease-related symptoms of kidney cancer.

W. Bro, D. Cella, S. Yount, 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Quality of life and psychosocial status in stage D prostate cancer

N. Vogelzang, M. Soloway, B. Cassileth, 1992, Quality of Life Research.

Patients' choice of treatment in stage D prostate cancer.

P. Schellhammer, G. Kennealey, N. Vogelzang, 1989, Urology.

Comparison of goserelin and leuprolide in combined androgen blockade therapy.

P. Schellhammer, E. Klein, N. Vogelzang, 1998, Urology.

Interleukin-1: biology, pathophysiology, and clinical prospects.

L. Platanias, N. Vogelzang, 1990, The American journal of medicine.

Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.

G. Shapiro, P. Schőffski, A. Daud, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does PC-SPEs interact with warfarin?

N. Vogelzang, L. Nahlik, N. Davis, 2002, The Journal of urology.

Enzalutamide--a major advance in the treatment of metastatic prostate cancer.

N. Vogelzang, 2012, The New England journal of medicine.

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

J. Reeves, B. Somer, N. Vogelzang, 2020, Clinical genitourinary cancer.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

E. Lam, B. Somer, N. Vogelzang, 2020, Clinical genitourinary cancer.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

I. Wistuba, J. Heymach, K. Kelly, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

M. Atkins, M. Fishman, E. Plimack, 2019, Cancer.

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA

N. Vogelzang, S. Pal, J. Signorovitch, 2017, International journal of urology : official journal of the Japanese Urological Association.

A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.

N. Vogelzang, S. Pal, 2013, Clinical genitourinary cancer.

Axitinib Versus Sorafenib in First‐Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2017, Clinical genitourinary cancer.

Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.

N. Vogelzang, S. Pal, 2011, Clinical genitourinary cancer.

Another step toward the cure of metastatic renal cell carcinoma?

N. Vogelzang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

P. Kantoff, M. Kattan, E. Small, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

P. Kantoff, F. Saad, C. Parker, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radium-223 vs EBRT for multiple painful bone metastases: the data favor radium-223.

N. Vogelzang, 2014, Oncology.

Impact of race on survival in men with metastatic hormone-refractory prostate cancer.

S. George, E. Small, N. Vogelzang, 2004, Urology.

Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second‐Line Hormonal Therapy (CALGB 9181)

M. Conaway, E. Small, N. Vogelzang, 2001 .

HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182

P. Kantoff, E. Winer, M. Conaway, 1999 .

A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

Dingcai Cao, E. Vokes, C. Ryan, 2004, Clinical Cancer Research.

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

R. Ferris, P. Moore, V. Ganju, 2022, Journal for ImmunoTherapy of Cancer.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

E. Schmidt, D. Hyman, D. Rasco, 2019, The Lancet. Oncology.

Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.

G. Bosl, N. Vogelzang, B. Kennedy, 1981, Annals of internal medicine.

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.

R. Schilsky, M. Ratain, S. Mani, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on

W. Samlowski, N. Vogelzang, B. Wong, 2008, BJU international.

Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.

M. Kris, L. Newman, N. Petrelli, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.

E. Jonasch, N. Vogelzang, Thomas E. Hutson, 2015, Clinical genitourinary cancer.

Development of novel immune interventions for prostate cancer.

N. Agarwal, N. Vogelzang, Sumanth Padmanabh, 2012, Clinical genitourinary cancer.

One hundred thirteen men with hormone-refractory prostate cancer died today.

N. Vogelzang, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma

S. Groshen, T. Dorff, I. Gill, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment options in metastatic renal carcinoma: an embarrassment of riches.

N. Vogelzang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, Platinum Analogues, and Other Heavy Metal Complexes

S. Ackland, N. Vogelzang, 1987 .

A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905).

I. Wistuba, D. Gandara, A. Tsao, 2013 .

Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.

B. Rini, L. Selk, N. Vogelzang, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

P. Albers, T. Choueiri, N. Agarwal, 2014, Clinical genitourinary cancer.

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

G. Sonpavde, W. Oh, M. Galsky, 2011, The Lancet. Oncology.

Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.

M. Stöckle, D. Huo, G. Steinberg, 2006, Clinical genitourinary cancer.

Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.

W. Stadler, N. Vogelzang, 1999, Urology.

Prognostic factors for survival in patients treated in phase I clinical trials

R. Schilsky, M. Ratain, R. Mick, 1994, Cancer.

Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.

D. Smith, E. Small, R. Kurzrock, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

David C. Smith, G. Shapiro, R. Kurzrock, 2017, European journal of cancer.

Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.

N. Vogelzang, S. Pal, N. Ruel, 2013, The Journal of urology.

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

M. Ratain, B. Goh, E. Vokes, 1999, Cancer.

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.

G. Scagliotti, R. Gaafar, N. Vogelzang, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

P. Catalano, L. Einhorn, E. Crawford, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.

T. Zimmerman, B. Rini, W. Stadler, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience

T. Zimmerman, B. Rini, W. Stadler, 2005, Bone Marrow Transplantation.

Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells

T. Zimmerman, B. Rini, N. Vogelzang, 2004, Bone Marrow Transplantation.

Modulation of vinblastine resistance with cyclosporine: A phase I study

R. Schilsky, M. Ratain, R. Mick, 1993, Clinical pharmacology and therapeutics.

Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy

N. Vogelzang, B. Kennedy, B. Samuels, 2004, Cancer Chemotherapy and Pharmacology.

Vascular and other complications of chemotherapy for testicular cancer

N. Vogelzang, 1984, World Journal of Urology.

A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia.

E. Vokes, R. Mick, N. Vogelzang, 1990, British Journal of Cancer.

Vascular toxicity following vinblastine, bleomycin, and cisplatin therapy for germ cell tumours.

N. Vogelzang, B. Kennedy, B. Samuels, 1987, International journal of andrology.

Prognostic factors in metastatic testicular cancer.

N. Vogelzang, 1987, International journal of andrology.

Vinblastine, bleomycin and cis-diamminedichloroplatinum in the treatment of advanced testicular carcinoma. Possible importance of longer induction and shorter maintenance schedules.

P. Lange, G. Bosl, J. Rosai, 1980, The American journal of medicine.

A human embryonal—yolk sac carcinoma model system in athymic mice

R. Vessella, N. Vogelzang, D. Bronson, 1985, Cancer.

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

N. Geller, J. Auman, H. Scher, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

G. Pond, P. Albers, T. Choueiri, 2013, European urology.

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy

G. Pond, T. Powles, G. Sonpavde, 2017, BJU international.

Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors.

G. Bosl, W. Whitmore, N. Vogelzang, 1985, The American journal of medicine.

Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.

P. Lange, N. Vogelzang, B. Kennedy, 1982, Cancer research.

A fixed-dose phase I study of ZD9331, a novel non-polyglutamated inhibitor of thymidylate synthase, in patients with refractory cancer

R. Schilsky, M. Ratain, B. Goh, 1999 .

Successful treatment of mediastinal germ cell/endodermal sinus tumors.

N. Vogelzang, B. Kennedy, R. Anderson, 1985, Chest.

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

G. Sonpavde, M. Ernstoff, M. Carducci, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin.

N. Vogelzang, R. Sibley, R. Harrell, 1982, The American journal of medicine.

Return of fertility after treatment for nonseminomatous testicular cancer: changing concepts.

P. Lange, P. Narayan, N. Vogelzang, 1983, The Journal of urology.

A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.

N. Vogelzang, S. Pal, R. Nelson, 2013, Clinical genitourinary cancer.

Phase I study of an oral formulation of ZD9331 administered daily for 28 days.

R. Schilsky, M. Ratain, M. Sawyer, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.

L. Norton, Michael Pollak, N. Vogelzang, 1991, Medical and pediatric oncology.

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

J. Lunceford, S. Culine, T. Powles, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.

A. Ravaud, T. Powles, B. Nelson, 2021, European urology.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study

David C. Smith, B. Somer, N. Stambler, 2019, The Prostate.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

J. Soria, J. Bendell, D. Sampath, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant mesothelioma: diagnostic and management strategies for 1992.

N. Vogelzang, 1992, Seminars in oncology.

Laboratory and clinical studies of biochemical modulation by hydroxyurea.

R. Schilsky, M. Ratain, E. Vokes, 1992, Seminars in oncology.

Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine.

N. Vogelzang, B. Kennedy, S. Ewing, 1980, Cancer treatment reports.

The n e w e n g l a n d j o u r n a l of m e d i c i n e Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

S. Fosså, D. Bottomley, J. Logue, 2022 .

5-Azacytidine and renal tubular dysfunction.

C. Bloomfield, A. Collins, N. Vogelzang, 1981, Blood.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

I. Thompson, C. Tangen, M. Carducci, 2018, Cancer treatment and research communications.

Tumor lysis syndrome after induction chemotherapy of small-cell bronchogenic carcinoma.

N. Vogelzang, R. A. Nelimark, K. Nath, 1983, JAMA.

Leukemia occurring after treatment of small cell lung cancer.

D. Arthur, N. Vogelzang, B. Kennedy, 1982, Cancer treatment reports.

EARLY FINDINGS CREATE BUZZ FOR POTENT NOVEL HORMONE BLOCKER DO YOU KNOW WHERE YOUR PROSTATE CANCER TISSUE IS

L. Fink, J. Khoury, N. Vogelzang, 2008 .

The role of transrectal aspiration biopsy in the diagnosis of prostatic cancer.

M. Bibbo, G. Wied, G. Steinberg, 1986, The Journal of urology.

Prognostic factors in renal carcinoma.

B. Rini, N. Vogelzang, 2000, Seminars in oncology.

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.

R. Schilsky, M. Ratain, N. Vogelzang, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-Escalating S tudy o f C apecitabine P lus G emcitabine Combination T herapy i n P atients W ith A dvanced C ancer

R. Schilsky, M. Ratain, N. Vogelzang, 2002 .

Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease.

N. Vogelzang, S. Pal, Jeremy O. Jones, 2014, Clinical genitourinary cancer.

Re: Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?

N. Vogelzang, A. Jani, 2001, The Journal of urology.

Two paths forward in metastatic castration-resistant prostate cancer.

N. Vogelzang, 2013, Oncology.

Interleukin-2 associated linear IgA bullous dermatosis.

N. Vogelzang, K. Soltani, M. Medenica, 1996, Journal of the American Academy of Dermatology.

Interleukin-2 dermatosis associated linear IgA bullous

N. Vogelzang, K. Soltani, M. Medenica, 1996 .

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2007, The Journal of urology.

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

S. Fosså, C. Parker, N. James, 2017, European urology.

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

M. Ratain, E. Vokes, C. Ryan, 2004, Clinical Cancer Research.

Association of interleukin‐2 therapy with staphylococcal bacteremia

N. Vogelzang, J. Richards, T. Gilewski, 1991, Cancer.

Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States

E. Jonasch, N. Vogelzang, D. George, 2015, Expert opinion on pharmacotherapy.

Corticosteroids in Advanced Cancer

N. Vogelzang, 2001 .

A Phase 1, Open–label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

E. Rasmussen, R. Kurzrock, M. Bass, 2016 .

Evaluation of neuropathy in patients on suramin treatment

M. Ratain, E. Vokes, B. Soliven, 1997, Muscle & nerve.

A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study

A. Benson, M. Tallman, T. Kuzel, 1993, Cancer.

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

N. Vogelzang, Shengyan Hong, C. Becerra, 2014, Cancer Chemotherapy and Pharmacology.

Human gene marker/therapy clinical protocols.

R. Haubrich, K. Cornetta, J. Roth, 1999, Human gene therapy.

Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782.

E. Small, J. Picus, N. Vogelzang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results

U. Harmenberg, C. Peschel, N. Vogelzang, 2007 .

Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acid

C. Ryan, D. Huo, W. Stadler, 2007, BJU international.

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

C. Higano, C. Sternberg, A. Bryce, 2021, Clinical Cancer Research.

A phase I study of subcutaneous recombinant interleukin‐2 and interferon alfa‐2a

M. Ratain, N. Vogelzang, L. Janisch, 1993, Cancer.

Retrospective Study of Real-World Treatment Patterns and Outcomes in Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Lenvatinib/Everolimus after Heavy Pretreatment1

N. Robert, N. Vogelzang, N. Tannir, 2021, Kidney Cancer.

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.

L Janish, M J Ratain, M. Ratain, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erythema multiforme induced by suramin.

N. Vogelzang, M. Medenica, K. Kobayashi, 1995, Journal of the American Academy of Dermatology.

Suramin: is adaptive control necessary?

M. Ratain, E. Vokes, N. Vogelzang, 1992, Journal of Clinical Oncology.

Chemotherapy for non-small cell lung cancer. The continuing challenge.

E. Vokes, N. Vogelzang, J. Bitran, 1991, Chest.

A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

W. Stadler, N. Vogelzang, M. Dumas, 2004, Investigational New Drugs.

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.

N. Vogelzang, A. Lipton, R. Figlin, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.

E. Plimack, R. DiPaola, A. Bryce, 2020, European urology oncology.

An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

E. Drea, N. Vogelzang, A. Morgans, 2022, BMC Health Services Research.

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

J. Leonard, M. Atkins, J. Sosman, 1997, Blood.

Second-line chemotherapy for advanced hormone-refractory prostate cancer.

O. Sartor, N. Vogelzang, S. Halabi, 2008, Clinical advances in hematology & oncology : H&O.

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

E. Plimack, R. DiPaola, M. Carducci, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.

Wen-Jeng Wu, Chao-yuan Huang, Chia‐Chi Lin, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study

J. Burke, J. Gschwend, C. Sternberg, 2017, JAMA oncology.

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA

C. Parker, P. Hoskin, S. Nilsson, 2016, The Prostate.

Effective chemotherapy for melanoma after treatment with interleukin‐2

N. Vogelzang, J. Richards, T. Gilewski, 1992, Cancer.

Phase I study of weekly 24-hour infusions of recombinant human interleukin-2.

N. Vogelzang, E. Barker, J. Richards, 1988, Journal of the National Cancer Institute.

Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.

A. Bryce, A. Patnaik, W. Abida, 2022, European urology.

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

D. Lake, E. Small, N. Vogelzang, 2000, Cancer.

S. Culine, M. Climent, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.

W. Stadler, N. Vogelzang, K. Shulman, 1996, Urology.

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

E. Small, N. Vogelzang, E. J. Small, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dihydro‐5‐azacytidine in malignant mesothelioma

M. Citron, J. Herndon, Mark R. Green, 1997, Cancer.

Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study

R. Schilsky, M. Ratain, J. Doroshow, 2004, Cancer Chemotherapy and Pharmacology.

Cancer chemotherapy and skin changes.

M. Ratain, N. Vogelzang, 1985, Annals of internal medicine.

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).

C. Baum, C. Peschel, N. Vogelzang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial.

S. Srinivas, A. Alva, D. Josephs, 2020 .

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer

B. Somer, S. Srinivas, N. Vogelzang, 2013, Investigational New Drugs.

A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.

P. Kantoff, H. Scher, J. Bono, 2013 .

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

M. Kattan, C. Parker, S. Nilsson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel.

R. DiPaola, M. Carducci, M. Kohli, 2017 .

The sand-trap hazard in magnetic resonance imaging.

N. Vogelzang, T. Kim, 1989, Annals of internal medicine.

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations.

H. Scher, A. Bryce, A. Patnaik, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting.

N. Robert, N. Vogelzang, N. Tannir, 2021, Clinical genitourinary cancer.

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

R. DiPaola, M. Carducci, M. Kohli, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I C linical a nd P harmacogenetic S tudy o f W eekly TAS-103 i n P atients W ith A dvanced C ancer

R. Schilsky, M. Ratain, Soma Das, 2001 .

Mediastinal nonseminomatous germ cell tumors: the role of combined modality therapy.

J. Rosai, N. Vogelzang, B. Kennedy, 1982, The Annals of thoracic surgery.

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

E. Vokes, R. Amato, W. Stadler, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I I T rial o f W eekly I ntravenous G emcitabine W ith Continuous I nfusion F luorouracil i n P atients W ith Metastatic R enal C ell C ancer

B. Rini, W. Stadler, N. Vogelzang, 2000 .

1.5-Year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA Study 9.

C. Parker, S. Nilsson, D. Bottomley, 2014, Clinical advances in hematology & oncology : H&O.

Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.

C. Parker, N. Vogelzang, J. O’Sullivan, 2013 .

714 PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES

C. Parker, S. Nilsson, N. Vogelzang, 2013 .

Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases : baseline prognostic factor subgroup analysis

N. James, N. Vogelzang, J. O’Sullivan, 2013 .

The ongoing evolution of dendritic cell therapy

N. Vogelzang, M. Sokoloff, N. Vogelzang, 1999, Cancer.

Bridging the gap: Health disparity research initiatives through the department of defense (DOD) congressionally directed medical research programs (CDMRP) prostate cancer research program (PCRP)

Jeffrey R. Smith, M. Roach, T. Carey, 2005 .

Adjuvant Androgen-Deprivation Therapy for Prostate Cancer: Should Docetaxel Be Added?

N. Vogelzang, 2019, JAMA oncology.

Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B

Mark R. Green, N. Vogelzang, J. Corson, 2004, Cancer Chemotherapy and Pharmacology.

Residual pulmonary nodules after combination chemotherapy of testicular cancer.

N. Vogelzang, R. Stenlund, 1983, Radiology.

A randomized phase II trial of Interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma.

E. Vokes, J. Kugler, W. Stadler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

R. Figlin, K. Foon, J. Gollob, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer

Sanjay Sharma, N. Vogelzang, G. Blumenschein, 2007 .

Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology

E. Messing, I. Thompson, C. Tangen, 2011 .

Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).

G. Sonpavde, M. Galsky, B. Hellerstedt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.

N. Vogelzang, V. Hárs, M. Taplin, 1999, Seminars in oncology.

Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.

N. Geller, H. Scher, G. Bosl, 1983, Cancer research.

Human renal cancer carcinogenesis: a review of recent advances.

W. Stadler, N. Vogelzang, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Selecting a secondary treatment.

N. Vogelzang, A. Jani, N. Davis, 2003, The Urologic clinics of North America.

Flt-3 Ligand and Sequential FL/Interleukin-2 in Patients With Metastatic Renal Carcinoma: Clinical and Biologic Activity

B. Rini, W. Stadler, N. Vogelzang, 2002, Journal of immunotherapy.

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.

R. DiPaola, M. Carducci, M. Kohli, 2018, European urology.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

David F Jarrard, Nicholas J Vogelzang, C. Kyriakopoulos, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

David F Jarrard, Yu-Ning Wong, Nicholas J Vogelzang, 2015, The New England journal of medicine.

Intermittent versus continuous androgen deprivation in prostate cancer.

Donna L Berry, Ian M Thompson, Stephen Prescott, 2013, The New England journal of medicine.

Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology.

J. V. Von Roenn, L. Ellis, M. Gilbert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.

R. Schilsky, M. Ratain, N. Vogelzang, 1994, Journal of the National Cancer Institute.

VP-16-213 (etoposide): the mandrake root from Issyk-Kul.

N. Vogelzang, B. Kennedy, D. Raghavan, 1982, The American journal of medicine.

Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.

C. Sternberg, N. Vogelzang, 2003, Critical reviews in oncology/hematology.

Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted?

S. Mani, N. Vogelzang, 1996, Hematology/oncology clinics of North America.

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

E. Vokes, J. Kugler, W. Stadler, 2006, Investigational New Drugs.

Nephrocalcin: biosynthesis by human renal carcinoma cells in vitro and in vivo.

E. K. Michaels, N. Vogelzang, F. Coe, 1992, Cancer research.

Weekly cisplatin plus infusional high‐dose 5‐fluorouracil and leucovorin (P‐HDFL) for metastatic urothelial carcinoma

Chih-Hung Hsu, Chao-yuan Huang, Y. Pu, 2006, Cancer.

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

N. Vogelzang, W. Edenfield, M. Eisenberger, 2015, Clinical Cancer Research.

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.

C. Shapiro, J. Sosman, T. Kuzel, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Buschke-Lowenstein tumor: therapeutic options including systemic chemotherapy.

N. Vogelzang, G. Chodak, G. Gerber, 1993, Urology.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Nicholas J Vogelzang, C. Tangen, H. Grossman, 2003, The New England journal of medicine.

Herpes Virus Latency in Spinal Ganglia of Mice Without Illness 4

G. Jackson, N. Vogelzang, R. Mckendall, 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.

M. Ratain, N. Vogelzang, D. V. Van Echo, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.

M F Sarosdy, E. Messing, D. Lamm, 1996, The Journal of urology.

Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.

R. Schilsky, M. Ratain, N. Cooper, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

J. Pinski, I. Thompson, T. Dorff, 2010, Clinical Cancer Research.

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

P. Kantoff, H. Scher, D. Rathkopf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute Changes of a-Fetoprotein and Human Chorionic Gonadotropinduring InductionChemotherapy of Germ Cell Tumors1

P. Lange, N. Vogelzang, B. Kennedy, 1982 .

Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors

Paul J Catalano, Donald Trump, P. Catalano, 2003, Cancer.

Marker half-life analysis as a prognostic tool in testicular cancer.

P. Lange, N. Vogelzang, B. Kennedy, 1982, The Journal of urology.

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

R. Motzer, J. Bacik, M. Mazumdar, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

S. Culine, M. Climent, T. Choueiri, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Nicholas J. Vogelzang, Jingsong Zhang, Michael Ong, 2017, JAMA oncology.

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

N. Geller, D. Bajorin, G. Bosl, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor classification and size in germ‐cell testicular cancer. Influence on the occurrence of metastases

P. Lange, G. Bosl, J. Rosai, 1982, Cancer.

A phase I study of intermittent infusion cladribine in patients with solid tumors

R. Schilsky, M. Ratain, E. Vokes, 1994, Cancer.

Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer

S. Mohile, N. Vogelzang, M. O'Rourke, 2021, JCO oncology practice.

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.

N. Geller, J. Auman, G. Bosl, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus statement on circulating tumour markers and staging patients with germ cell tumours.

N. Vogelzang, G. Rustin, D. T. Sleijfer, 1990, Progress in clinical and biological research.

Therapy for malignant pleural mesothelioma

H. Pass, M. Carbone, N. Vogelzang, 2006 .

Surgical treatment of patients with stages I and II nonseminomatous testicular cancer.

P. Lange, P. Narayan, N. Vogelzang, 1985, The Journal of urology.

Severe renal tubular dysfunction during 5-azacytidine chemotherapy

C. Bloomfield, A. Collins, N. Vogelzang, 1979 .

IMPACT OF DELAY IN DIAGNOSIS ON CLINICAL STAGE OF TESTICULAR CANCER

P. Lange, G. Bosl, N. Vogelzang, 1981, The Lancet.

Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

I. Thompson, C. Tangen, E. Crawford, 2009, Therapeutic advances in medical oncology.

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

E. Small, A. Kessinger, N. Vogelzang, 2008, Clinical genitourinary cancer.

Sequential therapy with dacarbazine and carmustine: a phase I study

R. Schilsky, M. Ratain, N. Vogelzang, 2004, Cancer Chemotherapy and Pharmacology.

Radiation induced renal cell cancer: a report of 4 cases and review of the literature.

Srinivasan Vijayakumar, N. Vogelzang, S. Goldman, 1999, The Journal of urology.

A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer

M. Ratain, E. Vokes, J. Kugler, 1999 .

Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study

M. Ratain, E. Vokes, N. Vogelzang, 2004, Cancer Chemotherapy and Pharmacology.

Emerging drugs for the treatment of metastatic renal cancer

W. Samlowski, N. Vogelzang, 2007, Expert opinion on emerging drugs.

New and promising strategies in the management of bladder cancer.

D. Theodorescu, N. Vogelzang, A. Apolo, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

C. Higano, C. Sternberg, A. Bryce, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

I. Taylor, H. Burris, D. Petrylak, 2020 .

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

S. Signoretti, T. Choueiri, N. Agarwal, 2017, European urology.

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone‐sensitive prostate cancer

I. Thompson, C. Tangen, M. Tewari, 2018, The Prostate.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

F. Saad, H. Scher, C. Sternberg, 2012, The Lancet. Oncology.

Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.

P. Hegde, A. Ravaud, T. Powles, 2018 .

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

M. Galsky, N. Vogelzang, M. Saleh, 2014, Clinical Cancer Research.

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

C. Ryan, W. Stadler, N. Vogelzang, 2002, Cancer Chemotherapy and Pharmacology.

Phase I Clinical and Pharmacological Study of O 6-Benzylguanine Followed by Carmustine in Patients with Advanced Cancer 1

R. Schilsky, M. Ratain, S. Mani, 2000 .

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

J. Herndon, Mark R. Green, N. Vogelzang, 1998, Chest.

Malignant pleural mesothelioma.

H. Pass, M. Carbone, N. Vogelzang, 1993, Current problems in surgery.

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.

P. Kantoff, E. Small, D. Hayes, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic S ignificance o f R everse T ranscriptase P olymerase Chain R eaction f or P rostate-Specifi c A ntigen i n M etastatic Prostate C ancer: A N ested S tudy W ithin C ALGB 9 583

P. Kantoff, E. Small, D. Hayes, 2003 .

Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma

Ximing J. Yang, B. Teh, M. Tretiakova, 2004, The American journal of surgical pathology.

Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?

N. Vogelzang, S. Sundararajan, 2015, Future oncology.

808OINHIBITION OF PD-L1 BY MPDL3280A LEADS TO CLINICAL ACTIVITY IN PTS WITH METASTATIC UROTHELIAL BLADDER CANCER (UBC).

P. Hegde, T. Powles, H. Burris, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

U. Harmenberg, C. Peschel, N. Vogelzang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.

P. Kantoff, E. Small, D. Hayes, 2001, Cancer research.

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

W. Pierceall, G. Shapiro, M. Borad, 2011, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Studies of CBP 501 , a G 2 Checkpoint Abrogator , as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

W. Pierceall, G. Shapiro, M. Borad, 2011 .

Biomarkers in renal cell carcinoma: Are we there yet?

N. Vogelzang, S. Gulati, 2021, Asian journal of urology.

A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma

David C. Smith, N. Vogelzang, S. Pal, 2019, Cancer.

Fever and granulocytopenia: a viewpoint from an academic setting.

N. Vogelzang, J. Flaherty, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Phase I and PharmaeoMnetie Study of a New Antineoplastie Agent : Pyrazine Diazohydroxide ( NSC 361456 ) 1

R. Schilsky, M. Ratain, R. Mick, 2007 .

Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).

R. Schilsky, M. Ratain, R. Mick, 1994, Cancer research.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

G. Scagliotti, N. Pavlakis, T. Nakano, 2019, The Lancet. Respiratory medicine.

Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors

L. Fink, D. Ward, Yupo Ma, 2009, Cancer Epidemiology Biomarkers & Prevention.

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

T. Powles, G. Sonpavde, M. Galsky, 2013, Clinical genitourinary cancer.

Interpatient and intrapatient variability in vinblastine pharmacokinetics

M. Ratain, N. Vogelzang, J. Sinkule, 1987, Clinical pharmacology and therapeutics.

Periwinkle Alkaloids I: Vinblastine and Vindesine

M. Ratain, N. Vogelzang, G. Bodey, 1987 .

Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.

N. Vogelzang, S. Pal, 2013, Clinical advances in hematology & oncology : H&O.

Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm

Nicholas J Vogelzang, D. Quinn, N. Vogelzang, 2012, Molecular Cancer Therapeutics.

Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

J. Leonard, M. Atkins, J. Sosman, 1997 .

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

G. Sonpavde, W. Oh, M. Galsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.

E. Small, N. Vogelzang, S. Halabi, 2006, The Journal of urology.

A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM)

C. Obasaju, K. Rosenzweig, V. Rusch, 2007 .

Blindness secondary to prostate cancer

N. Vogelzang, G. Chodak, David Olson, 1993, Supportive Care in Cancer.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

R. Figlin, R. Motzer, M. Voss, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes and prognosis in advanced renal cell carcinoma

M. Galsky, N. Vogelzang, 2007, Expert review of anticancer therapy.

Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.

M J Ratain, R. Schilsky, M. Ratain, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma

O. Elemento, J. Mosquera, G. Sonpavde, 2022, British Journal of Cancer.

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

S. Fosså, C. Parker, N. James, 2014, The Lancet. Oncology.

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

F. Saad, M. Morris, E. Small, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Castrate Resistant Prostate Cancer—Recent Advances and Optimal Sequence of Treatments

N. Agarwal, G. Sonpavde, J. Bellmunt, 2013, Current Urology Reports.

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Susan Halabi, Ian F Tannock, Ian M Thompson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

I. Thompson, C. Tangen, E. Crawford, 2012, The Journal of urology.

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Textbook of Genitourinary Oncology

N. Vogelzang, 1996 .

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

I. Thompson, C. Tangen, E. Crawford, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate.

L. Fink, J. Khoury, N. Vogelzang, 2010, Archives of pathology & laboratory medicine.

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

S. Srinivas, C. Kuo, N. Vogelzang, 2008, Cancer investigation.

Granulocyte‐macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma

C. Ryan, T. Kuzel, W. Stadler, 2000, Cancer.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial

E. Messing, I. Thompson, C. Tangen, 2018, JAMA.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

J. Burke, J. Gschwend, C. Sternberg, 2015, The Lancet. Oncology.

Objective Measures of Physical Functional Capacity Warrant Exploration to Complement or Replace the Subjective Physician Estimated Performance Status

G. Sonpavde, M. Galsky, V. Raghavan, 2012, American journal of clinical oncology.

Docetaxel-based combination therapy for castration-resistant prostate cancer.

M. Galsky, N. Vogelzang, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

K. Owzar, E. Small, N. Vogelzang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.

N. Vogelzang, E. Efstathiou, W. Berry, 2015 .

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

P. Kantoff, M. Morris, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

E. Small, B. Rini, J. Picus, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Thomas J. Smith, M. Somerfield, H. Scher, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

P. Kantoff, E. Winer, M. Conaway, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

I. Thompson, C. Tangen, N. Agarwal, 2013, The Lancet. Oncology.

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

A. Iagaru, M. Morris, A. Dicker, 2018, The oncologist.

Abstract CT-07: ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC)

N. Vogelzang, M. Taplin, J. Stephenson, 2012 .

Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone-Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome

P. Schellhammer, N. Vogelzang, M. Soloway, 2000 .

Does ‘granular cell’ renal cell carcinoma exist? Molecular and histological reclassification

M. Tretiakova, N. Vogelzang, J. Sugimura, 2007, Histopathology.

Classification of renal neoplasms based on molecular signatures.

Ximing J. Yang, K. Furge, B. Teh, 2006, The Journal of urology.

A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.

A. D'Amico, E. Small, N. Vogelzang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.

P. Kantoff, R. Vollmer, N. Vogelzang, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma

R. Vollmer, N. Vogelzang, N. Dawson, 1998, Cancer.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

R. Figlin, R. Motzer, M. Voss, 2017 .

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

Thomas J. Smith, D Andrew Loblaw, Thomas J Smith, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

I. Thompson, C. Tangen, L. Fink, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule

A. Patnaik, N. Vogelzang, M. Mita, 2007 .

Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma

R. Motzer, M. Mazumdar, K. Sell, 1995, Cancer.

The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.

N. Vogelzang, H. van Tinteren, M. Soloway, 1992, The Journal of urology.

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

S. Srinivas, D. Josephs, N. Vogelzang, 2021, BMC Cancer.

Laparoscopic pelvic lymph node dissection: a review of 103 consecutive cases.

D. Haraf, N. Vogelzang, G. Chodak, 1994, The Journal of urology.

A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies

N. Vogelzang, E. Schuck, S. Madajewicz, 2007 .

Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma

G. Sonpavde, N. Vogelzang, P. Grivas, 2021 .

Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

G. Sonpavde, B. Hellerstedt, N. Vogelzang, 2012, Clinical genitourinary cancer.

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1997, Urology.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, European urology.

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, Urology.

Local Progression After Operative Treatment of Metastatic Kidney Cancer

N. Vogelzang, T. Peabody, M. Simon, 2001, Clinical orthopaedics and related research.

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

R. Figlin, A. Belldegrun, P. Lange, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Original Articles: Kidney Cancer

J. Chmiel, S. Sener, N. Vogelzang, 1995 .

New agents in the management of advanced mesothelioma.

C. Porta, L. Mutti, N. Vogelzang, 2005, Seminars in oncology.

Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.

G L Rosner, G. Rosner, R. Schilsky, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

Michael C. Mosier, N. Vogelzang, N. Gabrail, 2017, Cancer management and research.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial

Y. Tai, I. Thompson, C. Tangen, 2015, International journal of cancer.

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Hong Tang, Matthew R Cooperberg, Andrew J Armstrong, 2019, Cancer.

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

R. Huddart, E. Gallardo, N. Agarwal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Sten Nilsson, Oliver Sartor, John Logue, 2014, The Lancet. Oncology.

Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.

N. Vogelzang, E. Swallow, S. Ravichandran, 2019, Clinical genitourinary cancer.

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.

N. Vogelzang, W. Reichmann, S. Pal, 2016, Clinical genitourinary cancer.

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

N. Vogelzang, V. Lesovoy, Thomas E. Hutson, 2013, The Lancet. Oncology.

Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma

J. Herndon, Mark R. Green, N. Vogelzang, 1999, Cancer.

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

J. Herndon, N. Vogelzang, M. Green, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States

E. Jonasch, N. Vogelzang, D. George, 2014, Current medical research and opinion.

Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices

E. Jonasch, N. Vogelzang, S. Pal, 2014, Current medical research and opinion.

Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.

N. Vogelzang, Thomas E. Hutson, M. Bhor, 2013, Clinical genitourinary cancer.

Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers.

D. Lamm, S. Millis, N. Vogelzang, 2016, European urology focus.

Real‐World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis

N. Agarwal, N. Vogelzang, S. Pal, 2017, Clinical genitourinary cancer.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

P. Kantoff, M. Cooperberg, P. Schellhammer, 2020, Prostate Cancer and Prostatic Diseases.

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

E. Van Cutsem, R. Kelley, C. Verslype, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

T. Powles, M. Fishman, S. Srinivas, 2017 .

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA

G. Pond, G. Naik, N. Agarwal, 2018, Cancer.

ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).

S. Srinivas, A. Alva, D. Josephs, 2019, Journal of Clinical Oncology.

Granulocyte‐macrophage‐colony stimulating factor in metastatic renal cell carcinoma

M. Ratain, B. Rini, W. Stadler, 1998, Cancer.

A Phase II Trial of Sequential Chemotherapy With Docetaxel and Methotrexate Followed by Gemcitabine and Cisplatin for Metastatic Urothelial Cancer

T. Zimmerman, C. Ryan, W. Stadler, 2005, American journal of clinical oncology.

Gemcitabine in the treatment of bladder cancer

C. Ryan, N. Vogelzang, 2000, Expert opinion on pharmacotherapy.

Metastatic bladder cancer: advances in treatment.

T. Kuzel, W. Stadler, N. Vogelzang, 1997, European journal of cancer.

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

S. Horning, G. Curt, J. Groopman, 2000, The oncologist.

Dihydro‐5‐azacytidine and cisplatin in the treatment of malignant mesothelioma

J. Herndon, Mark R. Green, N. Vogelzang, 1998, Cancer.

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

G. Sonpavde, M. Ernstoff, M. Carducci, 2014, Cancer.

Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study

P. Kantoff, E. Small, B. Woda, 2005, Clinical Cancer Research.

Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee.

J. Chmiel, S. Sener, N. Vogelzang, 1995, The Journal of urology.

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)

E. Messing, I. Thompson, C. Tangen, 2010, BJU international.

Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904

E. Vokes, R. Kratzke, Mark R. Green, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

Rebecca F. Halperin, Winnie S. Liang, N. Schork, 2021, PloS one.

Keratoacanthomas and skin neoplasms associated with suramin therapy.

E. Vokes, N. Vogelzang, K. Soltani, 1996, Archives of dermatology.

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

E. Vokes, C. Ryan, W. Stadler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J. Burke, A. Eisen, M. Kohli, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a Phase II Placebo‐controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small‐cell Lung Carcinoma

H. Kluger, D. Ramies, B. Hellerstedt, 2019, Clinical lung cancer.

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

David C. Smith, R. Berger, R. Kurzrock, 2017, European journal of cancer.

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

David C. Smith, E. Basch, H. Scher, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

E. Gelmann, E. Small, W. Stadler, 2004, Urologic oncology.

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

Susan Halabi, Nicholas J Vogelzang, P. Kantoff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

David C. Smith, E. Basch, A. Bennett, 2015, European urology.

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

C. Parker, J. Reuning-Scherer, S. Nilsson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer.

N. Vogelzang, M. Scholz, Nicholas Vogelzang, 2019, Clinical genitourinary cancer.

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

P. Kantoff, N. Stambler, D. Petrylak, 2019, The Prostate.

PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.

M. Morris, A. Tolcher, A. Armour, 2018 .

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

N. Vogelzang, 2017, Expert review of clinical pharmacology.

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study

T. Powles, H. Burris, J. Bellmunt, 2018, JAMA oncology.

A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.

A. Kibel, C. Drake, E. Antonarakis, 2013 .

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

J. Doroshow, D. Gandara, H. Lenz, 2006, Clinical Cancer Research.

Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer

F. Saad, D. Dearnaley, J. Nelson, 2005 .

Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC).

P. Bycott, N. Vogelzang, J. Tarazi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous infusion chemotherapy: a critical review.

N. Vogelzang, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

L. Fink, D. Ward, N. Vogelzang, 2011, Clinical genitourinary cancer.

Inverse correlation between body mass index and clinical outcomes in men with advanced castration–recurrent prostate cancer

E. Small, N. Vogelzang, S. Halabi, 2007, Cancer.

Renal pelvic cancer: a review of 611 patients treated in Illinois 1975-1985. Cancer Incidence and End Results Committee.

J. Chmiel, S. Sener, N. Vogelzang, 1992, Urology.

A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone (DP) with or without Lenalidomide (LEN) in Patients with Castrate-Resistant Prostate Cancer (CRPC): The Mainsail Trial

C. Sternberg, J. Bellmunt, D. Petrylak, 2012 .

Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.

N. Vogelzang, E. R. Priest, L. Borden, 1992, The Journal of urology.

Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma.

R. Bahnson, N. Vogelzang, H. S. Hu, 2003, Urologic oncology.

A high rate of venous thromboembolism in a multi‐institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

B. Rini, W. Stadler, N. Vogelzang, 2002, Cancer.

Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma.

T. Zimmerman, B. Rini, W. Stadler, 2001, The Journal of urology.

Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.

G. Rosner, R. Schilsky, M. Ratain, 1993, Journal of the National Cancer Institute.

Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte‐macrophage colony stimulating factor support

M. Ratain, E. Vokes, N. Vogelzang, 1996, Cancer.

Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.

R. Schilsky, M. Ratain, N. Vogelzang, 1988, Journal of the National Cancer Institute.

Predictors of Long‐Term Response With Pazopanib in Patients With Advanced Renal‐Cell Carcinoma

N. Vogelzang, Q. Ahmad, S. Ghate, 2018, Clinical genitourinary cancer.

Funding for clinical (patient-oriented) oncology research: current status and recommendations for improvement. American Society of Clinical Oncology.

P. Scardino, B. Weber, K. Offit, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pleuroperitoneal shunting for malignant pleural effusions

D. Skinner, A. Little, N. Vogelzang, 1986, Cancer.

Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group.

N. Vogelzang, M. Soloway, B. Cassileth, 1992, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.

Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee

A. D'Amico, D. Bajorin, J. Mohler, 2006, Clinical Cancer Research.

Clear cell sarcoma and selective IgM deficiency: A case report

J. Finlay, N. Vogelzang, R. Hong, 1982, Cancer.

Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.

R. Schilsky, M. Ratain, B. Goh, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention

N. Vogelzang, M. Moyad, 2015, Asian journal of andrology.

Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations

M. Ratain, B. Goh, W. Stadler, 2000, Cancer Chemotherapy and Pharmacology.

A phase I/II dose‐escalation study of exisulind and docetaxel in patients with hormone‐refractory prostate cancer

C. Ryan, W. Stadler, N. Vogelzang, 2005, BJU international.

SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).

I. Thompson, C. Tangen, N. Agarwal, 2012 .

Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).

G. Sonpavde, M. Galsky, B. Hellerstedt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Importance of serum hemoglobin in hormone refractory prostate cancer.

Robin T Vollmer, Nicholas J Vogelzang, P. Kantoff, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration‐Resistant Prostate Cancer Treated on SWOG Study S0421

G. Pond, I. Thompson, C. Tangen, 2017, Clinical genitourinary cancer.

Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).

J. Pinski, S. Ingles, I. Thompson, 2016 .

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

L. Fink, D. Ward, N. Vogelzang, 2011, Clinical genitourinary cancer.

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.

B. Rini, W. Stadler, N. Vogelzang, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

N. Agarwal, N. Vogelzang, S. Pal, 2017, Advances in Therapy.

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.

M. Carducci, O. Sartor, N. Vogelzang, 2004, Urology.

Hematologic Safety of Radium‐223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial

C. Parker, J. Michalski, S. Nilsson, 2017, Clinical genitourinary cancer.

Tobacco control: reducing cancer incidence and saving lives. American Society of Clinical Oncology.

P. Scardino, B. Weber, K. Offit, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 Study of Cabozantinib (XL184) in a Cohort of Patients With Castration-Resistant Prostate Cancer (CRPC) and Measurable Soft Tissue Disease

David C. Smith, E. Small, R. Kurzrock, 2011 .

Testosterone replacement in prostate cancer survivors with hypogonadal symptoms

T. Dorff, N. Vogelzang, S. Tucker, 2009, BJU international.

Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.

R. Schilsky, M. Ratain, L. Schumm, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).

S. Fosså, C. Parker, P. Hoskin, 2012 .

The scientific data audit system of the cancer and leukemia group B (CALGB)

L. Norton, N. Vogelzang, R. Weiss, 1992 .

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy

E. Small, J. Picus, N. Vogelzang, 2012, Cancer.

A Phase II Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer

S. Groshen, J. Pinski, M. Gross, 2014, Prostate Cancer and Prostatic Disease.

Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA)

C. Parker, S. Nilsson, N. Vogelzang, 2012 .

Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease

B. Somer, S. Srinivas, N. Vogelzang, 2011, Investigational New Drugs.

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

C. Parker, J. Reuning-Scherer, S. Nilsson, 2017, European journal of cancer.

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data

P. Kantoff, M. Cooperberg, A. Armstrong, 2020, Cancer.

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.

V. Khoo, Z. Filipovic, N. Vogelzang, 2022, JAMA oncology.

The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.

J. Holland, N. Vogelzang, A. Kornblith, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate Cancer

N. Vogelzang, M. Soloway, G. Chodak, 1991 .

INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGBE D2) PROSTATE CANCER

N. Vogelzang, M. Soloway, G. Chodak, 1991 .

A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy

C. Ryan, W. Stadler, N. Vogelzang, 2005, BJU international.

Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB.

M Mazumdar, R. Motzer, J. Bacik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

G. Rosner, M. Ratain, David Palchak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hydrocortisone W ith o r W ithout M itoxantrone i n M en W ith Hormone-Refractory P rostate C ancer: R esults o f t he C ancer and L eukemia G roup B 9 182 S tudy

P. Kantoff, E. Winer, M. Conaway, 1999 .

A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest

E. Vokes, D. Haraf, N. Vogelzang, 1995, Cancer Chemotherapy and Pharmacology.

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.

E. Plimack, R. DiPaola, A. Bryce, 2018 .

Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

E. Plimack, R. DiPaola, M. Carducci, 2022, Journal of Clinical Oncology.

A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma

G. Pond, P. Albers, T. Choueiri, 2014, BJU international.

2530 Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA

C. Parker, M. Morris, S. Nilsson, 2015 .

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

S. Jain, R. Motzer, J. Hsieh, 2021, The Lancet. Oncology.

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

I. Thompson, C. Tangen, A. Goldkorn, 2014, Journal of the National Cancer Institute.

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

S. Steinberg, B. Bochner, D. Bajorin, 2014, Urologic oncology.

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

M. Meng, I. Thompson, C. Tangen, 2019, Kidney Cancer.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Susan M. Chang, Nicholas J Vogelzang, J. V. Von Roenn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: An Illinois Cancer Council study

M. Cobleigh, N. Vogelzang, T. Lad, 1989, Investigational New Drugs.

K. Rahbar, M. Morris, B. Krause, 2021, Annals of Oncology.

776PA PHASE 1/2 STUDY OF AT13387, A HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR IN COMBINATION WITH ABIRATERONE ACETATE (AA) AND PREDNISONE (P) IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) NO LONGER RESPONDING TO AA.

F. Saad, E. Gelmann, F. Kabbinavar, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

H. Scher, A. Bryce, A. Patnaik, 2018 .

Limited sampling model for vinblastine pharmacokinetics.

M J Ratain, M. Ratain, N. Vogelzang, 1987, Cancer treatment reports.

Signal‐transduction inhibitors in renal cell carcinoma

C. Sternberg, N. Vogelzang, 2007, BJU international.

Adding Docetaxel to Androgen-Deprivation Therapy in Newly Diagnosed Metastatic Prostate Cancer

N. Vogelzang, 2014 .

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

T. Powles, E. Plimack, A. Balar, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).

E. Small, W. Stadler, N. Vogelzang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

P. Kantoff, P. Humphrey, E. Small, 2006, Clinical genitourinary cancer.

INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.

I. Thompson, C. Tangen, B. Costello, 2021, Journal of Clinical Oncology.

Elimination pathways of [14C]losoxantrone in four cancer patients.

M. Ratain, E. Vokes, H. Pieniaszek, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Phase II study of echinomycin in patients with advanced breast cancer: A report of cancer and leukemia group B protocol 8641

R. Schilsky, D. Faraggi, W. Wood, 1991, Investigational New Drugs.

Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.

N. Vogelzang, Thomas E. Hutson, R. Dhanda, 2014, Clinical genitourinary cancer.

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

I. Thompson, C. Tangen, C. Moinpour, 2018, Journal of Patient-Reported Outcomes.

I. Thompson, C. Tangen, C. Moinpour, 2018 .

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

C. Higano, K. Kern, L. Appleman, 2023, Journal for ImmunoTherapy of Cancer.

Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.

N. Agarwal, C. Sternberg, A. Balar, 2020 .

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

P. Kantoff, M. Cooperberg, P. Schellhammer, 2020, Prostate Cancer and Prostatic Diseases.

CKD-EPI and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

N. Vogelzang, S. Pal, Mark Chang, 2014, PloS one.

Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).

S. Culine, M. Climent, T. Choueiri, 2018 .

Molecular profiling of infiltrating urothelial carcinoma of the bladder.

S. Millis, Z. Gatalica, N. Vogelzang, 2014 .

Erattum: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial (Urology (September 1997) 50 (330-336))

P. Schellhammer, N. Vogelzang, M. Soloway, 1998 .

Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?

N. Vogelzang, 2018, European urology.

Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results.

J. Maroto, N. Vogelzang, I. Durán, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?

G. Sonpavde, M. Galsky, N. Vogelzang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

S. Groshen, T. Dorff, D. Quinn, 2021, Annals of Oncology.

Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.

W. Stadler, N. Vogelzang, 1995, Seminars in oncology.

The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group.

O. Dalesio, N. Vogelzang, M. Soloway, 1990, Progress in clinical and biological research.

Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.

N. Agarwal, E. Lam, N. Vogelzang, 2018 .

Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma

A. Mansfield, N. Vogelzang, T. Peikert, 2018, Mayo Clinic proceedings.

A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.

N. Vogelzang, R. Weiss, L. Panasci, 1993, JAMA.

Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer

E. Vokes, W. Stadler, N. Vogelzang, 2004, Cancer Chemotherapy and Pharmacology.

Patterns of care related to age of men with prostate cancer

R. Elashoff, S. Greenfield, P. Ganz, 1991, Cancer.

Phase I Clinical and Pharmacological Study of lododeoxyuridine and Bleomycin in Patients with Advanced Cancer 1

R. Schilsky, M. Ratain, R. Mick, 2006 .

Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.

R. Schilsky, M. Ratain, R. Mick, 1993, Cancer research.

Esorubicin (4′‐Deoxydoxorubicin, NSC 267469) in Advanced Breast Cancer: A Phase II Study of the CALGB

W. Wood, N. Vogelzang, I. Henderson, 1990, American journal of clinical oncology.

Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.

B. Somer, W. Samlowski, N. Vogelzang, 2016, Journal of Clinical Oncology.

Multiple myeloma: detecting the eff ects of new treatments

J. Shamash, N. Vogelzang, R. Rudd, 2008 .

1152 Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study

T. Kuzel, W. Stadler, N. Vogelzang, 1995 .

Prognostic M odel f or P redicting S urvival i n M en W ith Hormone-Refracto ry M etastatic P rostate C ancer

P. Kantoff, M. Kattan, E. Small, 2003 .

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

J. Herndon, G. Strauss, N. Vogelzang, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Estimated potency of casodex: A problematic design [1] (multiple letters)

P. Schellhammer, J. Simard, N. Vogelzang, 1997 .

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

R. Ramlau, E. Antonarakis, N. Vogelzang, 2021, Annals of Oncology.

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

P. Kantoff, N. Stambler, N. Vogelzang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

P. Schellhammer, I. Thompson, C. Tangen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review

E. Jonasch, N. Vogelzang, W. Reichmann, 2016, Current medical research and opinion.

2510 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA

C. Parker, S. Nilsson, O. Sartor, 2015 .

Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP).

A. Iagaru, M. Morris, A. Dicker, 2015 .

Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer.

L. Fink, D. Ward, Yupo Ma, 2010, American journal of clinical pathology.

Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).

N. Vogelzang, M. Eisenberger, M. Taplin, 2012 .

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, H. Scher, C. Logothetis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

M. Ratain, E. Vokes, D. Lebwohl, 1999, Cancer Chemotherapy and Pharmacology.

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

A. D'Amico, P. Kantoff, E. Small, 2008, Urology.

Effect of radium-223 dichloride (Ra-223) on pain from US EAP.

M. Morris, N. Vogelzang, C. Sweeney, 2015 .

A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors

N. Geller, J. Auman, H. Scher, 1989 .

Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?

N. Vogelzang, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study.

N. Vogelzang, G. Locker, P. Bonomi, 1986, Cancer treatment reports.

A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).

T. Choueiri, F. Kabbinavar, D. Cho, 2012 .

Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient.

N. Vogelzang, 1990, The Journal of urology.

Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).

David C. Smith, H. Scher, J. Bono, 2012 .

F. Saad, H. Scher, C. Logothetis, 2012, Journal of Clinical Oncology.

Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.

E. Schmidt, D. Rasco, C. Aghajanian, 2018 .

Clinical staging of prostate cancer: Reproducibility and clarification of issues

Srinivasan Vijayakumar, Alan Pollack, James Montie, 2001, International journal of cancer.

Radiologic Assessment of Mesothelioma

S. Armato, H. MacMahon, N. Vogelzang, 2005 .

A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388).

N. Vogelzang, R. Dreicer, D. George, 2020 .

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

John Paul Shen, C. Sternberg, E. Heath, 2022, Journal of Clinical Oncology.

INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806.

Ronald C. Chen, I. Thompson, C. Tangen, 2020 .

The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.

E. Small, N. Vogelzang, S. Halabi, 2007, The Journal of urology.

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza).

A. Ross, N. Vogelzang, N. Gabrail, 2021 .

7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC)

H. Scher, D. Rathkopf, J. Picus, 2009 .

Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC).

H. Scher, D. Rathkopf, N. Vogelzang, 2009, Journal of Clinical Oncology.

Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer.

J. Bendell, J. Infante, L. Fecher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

Ximing J. Yang, T. Zimmerman, C. Ryan, 2003, The Journal of urology.

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

I. Thompson, C. Tangen, N. Agarwal, 2017, Kidney cancer.

Integrative Tumor Board: Metastatic Renal Cell Carcinoma

N. Vogelzang, Supriya K. Gupta, 2004, Integrative Cancer Therapies.

A Phase II trial of intravenous gemcitabine and 5‐fluorouracil with subcutaneous interleukin‐2 and interferon‐α in patients with metastatic renal cell carcinoma

C. Ryan, W. Stadler, N. Vogelzang, 2002 .

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.

A. D'Amico, C. Tempany, E. Small, 2008, International journal of radiation oncology, biology, physics.

A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.

E. Schmidt, D. Rasco, M. Brose, 2018 .

CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer

J. Sosman, E. Vokes, J. Kugler, 2000, Investigational New Drugs.

Kidney cancer

W. Stadler, N. Vogelzang, 1998, The Lancet.

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era

R. Motzer, N. Robert, N. Vogelzang, 2023, European urology open science.

P1.05A ph 1 study of 2 different schedules of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with rec Met Cast-Resist PC (MCRPC)

A. Tolcher, N. Vogelzang, S. Ejadi, 2015 .

Neurotoxicity after treatment with muromonab-CD3.

J. Bluestone, N. Vogelzang, J. Richards, 1990, The New England journal of medicine.

Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291.

J. Doroshow, D. Gandara, E. Vokes, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine.

M. Ratain, N. Vogelzang, C. L. Bennett, 1986, Cancer treatment reports.

EFFICACY AND SAFETY OF RADIUM‐223 BY RADICAL LOCAL THERAPY AT INITIAL DIAGNOSIS: A RETROSPECTIVE SUBGROUP ANALYSIS OF ALSYMPCA TRIAL: PD24‐07

C. Parker, L. Klotz, A. Dicker, 2017 .

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).

A. Bryce, A. Patnaik, W. Abida, 2020 .

Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study.

T. Powles, H. Burris, J. Bellmunt, 2017 .

Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC).

Y. Tai, I. Thompson, C. Tangen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.

M. Leblanc, C. Tangen, N. Agarwal, 2023, European urology.

Long-term response in primary renal cancer to sequential antiangiogenic therapy.

W. Samlowski, N. Vogelzang, A. Weissman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle.

E. Sausville, P. LoRusso, W. Samlowski, 2010 .

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.

C. Ryan, W. Stadler, N. Vogelzang, 2002, Cancer.

A multicenter phase 2 trial of neo-adjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM)

L. Bloss, C. Obasaju, V. Rusch, 2005 .

Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124.

I. Thompson, C. Tangen, E. Crawford, 2017 .

The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer.

S. Mohile, N. Vogelzang, W. Dale, 2021, The oncologist.

Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.

Heber MacMahon, Samuel G Armato, Masha Kocherginsky, 2005, Academic radiology.

Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).

M. Cooperberg, A. Armstrong, C. Higano, 2014, Clinical advances in hematology & oncology : H&O.

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001).

J. Brugarolas, E. Lam, B. Rini, 2022, Journal of Clinical Oncology.

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

P. Hegde, E. V. Van Allen, T. Powles, 2015, Journal of Immunotherapy for Cancer.

Cisplatin‐based chemotherapy in a renal transplant recipient

N. Vogelzang, 1992, Cancer.

Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma

John D. Roberts, N. Vogelzang, J. Atkins, 2002, Cancer.

Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.

E. Lam, B. Somer, N. Vogelzang, 2019, Journal of Clinical Oncology.

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data

N. Agarwal, N. Vogelzang, S. Pal, 2018, Journal of Managed Care & Specialty Pharmacy.

PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward.

Parminder Singh, N. Vogelzang, S. Pal, 2015, Clinical genitourinary cancer.

SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC).

I. Thompson, C. Tangen, N. Agarwal, 2015 .

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

I. Thompson, C. Tangen, N. Agarwal, 2020, Prostate Cancer and Prostatic Diseases.

Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

W. Oh, H. Pandha, K. Miller, 2015 .

Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

E. Basch, H. Scher, J. Bono, 2015 .

Prostate brachytherapy

A. D'Amico, N. Vogelzang, 1999, Cancer.

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

S. Culine, T. Choueiri, D. Bajorin, 2022, Journal of Clinical Oncology.

Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study

A. Ravaud, T. Powles, B. Nelson, 2019, Annals of Oncology.

Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.

T. Powles, M. Climent, E. Plimack, 2022, Journal of Clinical Oncology.

LBA37_PRPembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial

S. Culine, M. Climent, T. Choueiri, 2017 .

Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).

S. Culine, M. Climent, T. Choueiri, 2017 .

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

J. Pinski, S. Ingles, I. Thompson, 2021, Clinical Cancer Research.

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

I. Thompson, C. Tangen, N. Agarwal, 2022, Journal of Clinical Oncology.

Third-party reimbursement issues during a phase I trial of interleukin-2.

N. Vogelzang, J. Richards, 1989, Journal of the National Cancer Institute.

APF530 for nausea and vomiting prevention following cisplatin: phase 3 MAGIC trial analysis

Michael C. Mosier, N. Vogelzang, R. Geller, 2017 .

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma

A. Rademaker, W. Gradishar, A. Benson, 2004, Investigational New Drugs.

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study.

A. Rademaker, W. Gradishar, A. Benson, 1995, Investigational new drugs.

Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator.

W. Stadler, N. Vogelzang, J. Richards, 1992, Journal of the National Cancer Institute.

Molecular characterization of bladder cancer in smokers versus non-smokers.

D. Lamm, S. Millis, N. Vogelzang, 2015 .

Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results

U. Harmenberg, C. Peschel, N. Vogelzang, 2007 .

A review of chemotherapy trials for malignant mesothelioma.

C. Ryan, N. Vogelzang, J. Herndon, 1998, Chest.

Phase I S tudy o f a n O ral F ormulation o f Z D9331 A dministered Daily f or 2 8 D ays

R. Schilsky, M. Ratain, M. Sawyer, 2003 .

Vindesine in bronchogenic carcinoma: a phase II trial.

N. Vogelzang, B. Kennedy, B. Peterson, 1982, American journal of clinical oncology.

Molecular analysis of sarcomatoid renal cell carcinoma (sRCC).

T. Ho, S. Millis, E. Castle, 2015 .

Multiplatform molecular analysis of biomarkers in renal cell carcinoma.

T. Ho, S. Millis, Z. Gatalica, 2015 .

K. Rahbar, M. Morris, M. Desilvio, 2023, The Lancet. Oncology.

Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

E. Heath, T. Buchler, N. Vogelzang, 2021 .

Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.

P. Kantoff, M. Cooperberg, P. Schellhammer, 2019, Journal of Clinical Oncology.

Hormone-refractory prostate cancer: an evolving standard of care.

E. Small, N. Vogelzang, D. Reese, 1999, Seminars in oncology.

Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).

M. Morris, A. Tolcher, A. Armour, 2015 .

Phase I study to evaluate multiple regimens of intravenous 5‐fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors

R. Schilsky, M. Ratain, S. Mani, 2001, Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.

M J Ratain, M. Ratain, N. Vogelzang, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

T. Powles, N. Vogelzang, J. Bellmunt, 2017, Cancer treatment reviews.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

P. Hegde, T. Powles, H. Burris, 2014, Nature.

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

C. Parker, S. Nilsson, O. Sartor, 2017, European Journal of Cancer.

Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

G. Sonpavde, N. Vogelzang, M. Fleming, 2013, Journal of Clinical Oncology.

Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.

B. Rini, N. Vogelzang, P. Barata, 2017 .

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

M. Galsky, N. Vogelzang, D. Thornton, 2014, Clinical Cancer Research.

Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

N. Vogelzang, T. Karrison, G. Demir, 1998, Cancer.

A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM).

J. Villano, W. Stadler, N. Vogelzang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

E. Small, Y. Whang, J. Picus, 2011, Cancer.

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

David C. Smith, B. Somer, N. Stambler, 2015 .

Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

S. Culine, M. Climent, T. Choueiri, 2018 .

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

J. Burke, J. Hainsworth, C. Sternberg, 2017, European Urology.

Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1991, Urology.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

David C. Smith, E. Small, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

C. Tangen, C. Higano, E. Small, 2012, The Journal of urology.

Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease.

N. Vogelzang, S. Pal, Jeremy O. Jones, 2014, Clinical genitourinary cancer.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

David C. Smith, E. Basch, A. Bennett, 2015, European urology.

Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors

L. Fink, D. Ward, Yupo Ma, 2009, Cancer Epidemiology Biomarkers & Prevention.

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group.

N. Vogelzang, G. Chodak, Richard J. Caplan, 1991, JAMA.

A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.

S. Jain, E. Schmidt, D. Rasco, 2019, Journal of Clinical Oncology.

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.

T. Kuzel, W. Stadler, N. Vogelzang, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.

A. Wyatt, N. Vogelzang, A. Cesano, 2023, Journal of Clinical Oncology.

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

C. Tangen, N. Agarwal, E. Lam, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-431 Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model

N. Vogelzang, J. Rusthoven, J. Symanowski, 2005 .

Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).

H. Kluger, D. Ramies, B. Hellerstedt, 2012 .

The Tumor Lysis Syndrome-Reply

N. Vogelzang, 1983 .

Conclusion and Future Directions

W. Samlowski, N. Vogelzang, 2008, Cancer journal.

Novel agents for the treatment of advanced kidney cancer.

N. Vogelzang, M. Cooney, S. Remick, 2004, Clinical advances in hematology & oncology : H&O.

Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D).

R. DiPaola, M. Carducci, M. Kohli, 2017 .

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

A. Kibel, C. Drake, E. Antonarakis, 2016, Clinical Cancer Research.

A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM).

J. Villano, N. Vogelzang, A. Husain, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular profiling of infiltrating urothelial carcinoma of the bladder.

S. Millis, Z. Gatalica, N. Vogelzang, 2014 .

Advanced prostate cancer 2010: what a year!

O. Sartor, N. Vogelzang, 2010, Clinical genitourinary cancer.

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

C. Parker, J. Michalski, S. Nilsson, 2016, European urology.

Future Challenges for Drug Development in Renal Cell Carcinoma.

B. Rini, N. Vogelzang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC)

P. Hegde, T. Powles, D. Petrylak, 2014 .

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

P. Hegde, T. Powles, D. Petrylak, 2014, Journal of Immunotherapy for Cancer.

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

G. Sonpavde, M. Galsky, C. Sternberg, 2010, The Lancet. Oncology.

Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO).

S. Steinberg, B. Bochner, D. Bajorin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulocyte-Macrophage-Colony Stimulating Factor in Metastatic Renal Cell Carcinoma. A Phase II Trial

M. Ratain, B. Rini, W. Stadler, 1999 .